购买
语言
English
简体中文
繁體中文
对免疫健康的功效
菜单
对免疫健康的功效


健康肠道微生物群＝健康免疫系统

LACTOGG®益生菌有助于建立强壮有活力的肠道微生物生态系统，而微生物生态系统又反过来建立健康平衡的免疫系统。

肠道中珠珠益生菌的存在有利于促进一个多样而强健的微生物群落的生长。此外，适当数量的膳食纤维，低聚果糖（FOS）——低聚果糖是力多珠珠®固体饮料的原料之一，带来益生元效益，促进其他有益菌如双歧杆菌的生长。

在出生后的头2个月里，给予早产儿珠珠益生菌，其呼吸道感染，尤其是病毒性感染的发病次数会降低。

临床试验已证实LACTOGG®益生菌能提高免疫力，从而带来显著健康功效。

部分临床研究发现成果如下：

• 孕期服用珠珠益生菌的妈妈，能在其羊水和胎盘中发现珠珠益生菌的DNA。对这些珠珠母亲刚生下来的宝宝进行研究测试，发现相比于其他非珠珠宝宝，这些宝宝免疫系统更加成熟。

• 服用珠珠益生菌的婴儿，研究发现其体内分泌抗体的免疫细胞数量增加，免疫力也发育得更完善。

一岁宝宝免疫球蛋白分泌细胞数量对比。珠珠益生菌促进分泌免疫球蛋白M，免疫球蛋白A和免疫球蛋白G的细胞的生长。[Rinne et al. 2005]

• 孕期和出生后前6个月接触了珠珠益生菌的宝宝患过敏性湿疹的概率降低了50%。珠珠宝宝体内有更高水平的免疫调节因子，可以减少过敏炎症。

• 过敏性使者、牛奶过敏和过敏性鼻炎等过敏症患者服用珠珠益生菌后过敏症状得到显著改善。其免疫系统同样也显示出较少的过敏特征。

• 牛奶过敏的婴儿在出生后第一年如果坚持每日服用珠珠益生菌，其过敏能更快恢复。

• 服用珠珠益生菌的儿童患肠胃感染（肠胃炎）的几率更小，从肠胃感染中恢复更快。

• 研究发现婴儿、学步儿童、大龄儿童能更好抵抗感染，对抗生素的需求更小。这种免疫力的提高在后续很长时间内仍然明显。

儿童在三年多时间里使用抗生素（大环内酯类）的总数。虚线指连续七个月服用珠珠益生菌，开始停掉珠珠益生菌的时间点。与未服用益生菌的儿童相比，珠珠组儿童在三年多时间里使用的抗生素数量要少48%。
[Korpela et al. 2016]

• 成年人也有同样功效，研究发现成人抵抗感染能力提高，比如肺部感染和旅行腹泻。

• 医院已将将其用于清除儿童及成人肠道内的超级病菌。

• 遭受肠炎困扰的儿童及成人，服用珠珠益生菌后炎症有所减少。

服用鼠李糖乳杆菌GG后，粪钙卫蛋白（肠道炎症指数）数量减少。
[Bruzzese E et al. 2014]

• 注射疫苗期间，如果服用珠珠益生菌，人体对疫苗的免疫反应显著增强。

• 饮酒会导致胃肠道和肝组织产生炎症，进而造成肝损伤。服用珠珠益生菌能预防和逆转肝组织炎症，因为其能增加调节性T细胞，并减少负责触发肠道和肝组织炎症的免疫细胞数目。

LACTOGG®与免疫系统“对话”的能力意味着，LACTOGG®益生菌可以“教育” 、成熟、刺激和平衡人体免疫系统。

我们可以利用乐多珠珠®胶囊和力多珠珠®冲剂，对免疫系统进行长期的、健康的刺激和提高。



如何服用 LACTOGG®益生菌？

婴儿、儿童及成人

每日至少一粒胶囊或一袋固体饮料。




参考链接:

Cox MJ et al. Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome. PLoS ONE 2010;5(1):e8745

Luoto R et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial. J Allergy Clin Immunol 2014;133:405-13

Rautava S et al. Probiotics modulate host-microbe interaction in the placenta and fetal gut: A randomized, double-blind, placebo-controlled trial. Neonatology 2012;102:178-184

Kalliomaki M et al. Probiotic in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-1079

Marschan E et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 2008;38:611-618

Viljanen M et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005;60:494-500

Isolauri E et al. Probiotics in management of atopic eczema. Chin Exp Allergy 2000;30:1604-1610

Piirainen L et al. Effect of Lactobacillus rhamnosus GG on rBet v1 and rMal d1 specific IgA in the saliva of patients with birch pollen allergy. Ann Allergy Asthma Immunol 2008;100(4):338-342

Kawase M et al. Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study. Int J Food Microbiol 2009;128(3):429-434

Majamaa H et al. Probiotic: A novel approach in the management of food allergy. J Allergy Clin Immunol 1997;99:179-185

Pohjavuori E et al. Lactobacillus GG effect in increasing IFN-ɣ production in infants with cow's milk allergy. J Allergy Clin Immunol 2004:114:131-136

Berni Canani R et al. Effect of Lactobacillus GG on tolerance acquisition in infants with cow’s milk allergy: A randomized trial. J Allergy Clin Immunol 2012;129(2):580-581

Berni Canani R et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007;335(7615):340

Kaila M et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human L. strain. Pediatr Res1992;32(2):141-144

Guandalini S et al. Lactobacillus GG admin in oral rehydration solution to children with acute diarrhoea: A Multicenter European Trial. J Pediatr Gastrpenterol Nutr 2000;30(1):54-60

Oberhelman R et al. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr 1999;134:15-20  

Szajewska H et al. Efficacy of Lactobacillus GG in prevention of  nosocomial diarrhea in infants. J Pediatr 2001;138:361-365

Korpela K et al. Lactobacillus rhamnosus GG intake modifies preschool children's intestinal microbiota, alleviates penicillin-associated changes, and reduces antibiotic use. PLoS ONE 2016

Hojsak I et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 2010;125(5):e1171-7

Hatakka K et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001:322(7298):1327

Hojsak I et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day car centers: A randomized, double-blind, placebo-controlled trial. Clin Nutr 2009

Kukkonen K et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Paediatrics 2008;122:8-12

Morrow LE et al. Probiotic prophylaxis of ventilator-associated pneumonia. A blinded, randomized, controlled trial. Am J Resp Crit Care Med 2010;182:1058-1064

Oksanen PJ  et al. Prevention of travellers' diarrhoea by Lactobacillus GG. Ann Med 1990;22:53-56

Szachta P et al. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant entercocci in colonized children. J Clin Gastroenterol 2011:45(10):872-877

Manley KJ et al. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust 2007;186(9):454-457

Cheng VCC et al. Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature. BMC Infect Dis 2014;14-514

Bruzzese Eet al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: A randomised clinical trial. PLoS ONE 2014;9(2):e87796

Malin M et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996;40:137-145

Gosselink MP et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004;47(6):876-884

Zocco MA et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.Aliment Pharmacol Ther 2006;23:1567-1574

Davidson LE et al. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomised double-blind placebo controlled trial. Eur J Clin Nutr 2011;65:501-507

de Vrese M et al. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. Eur J Nutr 2005;44(7):406-413

Chen R-C et al. Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding. Toxicol Lett 2016;241:103-110

Bajaj JS et al. Randomized clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014;39(10):1113-1125

Hammes TO et al. Lactobacillus rhamnosus GG reduces hepatic fibrosis in a model of chronic liver disease in rats. Nutr Hosp 2017;34(3):702-709


购买
关注我们 websiteusers@lactogg.com 宣传册 政策声明 词汇表
香港特别行政区 倍迪康（香港）有限公司 香港金钟道95号统一中心18楼 固定电话:+852 3486 7233 传真:+852 3486 3723 中国 广州新键系生物科技有限公司 中华人民共和国广州国际生物岛螺旋四路
7号501-1单元 固定电话:+0757 26616888 传真:+0757 26382288
新加坡 ProbioCare Pte. Ltd. (201603757R) 32 Ean Kiam Place
Singapore 429119 固定电话:+65 6255 5592 Fax: +65 6255 5563 马来西亚 ProbioCare Sdn. Bhd. (1124987-P) 122 Jalan Ipoh
51200 Kuala Lumpur
Malaysia 固定电话:+603 2011 1223 传真:+603 2094 7723 文莱 Am Prolife Company (P20017787) P.O. Box 31, Jalan Gadong
BE3919, Brunei Darulssalam 固定电话:+673 7335566
邮箱:amprolifebn@gmail.com 泰国 Paedicare (Thailand) Co. Ltd 973 President Tower, Level 14
Unit D and E (1423) Ploenchit Road, Lumpini,
Pathumwan, Bangkok 10330, Thailand 固定电话:+66 99 2828338